Lexicon expects delay in FDA feedback on additional data for its diabetes drug
RefinitivThời gian đọc: dưới 1 phút
Lexicon Pharmaceuticals 
LXRX said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.
Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này